Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary
August 13, 2025
Earnings Call Speaker Segments
Ed Berg
executiveGood afternoon, everyone, and thanks for joining us on today's call. With us from Vaxart are Steven Lo, our Chief Executive Officer; Dr. Sean Tucker, our Founder and Chief Scientific Officer; Dr. James Cummings, our Chief Medical Officer; and Jeroen Grasman, our Chief Financial Officer. Before we get started, I want to remind all of you that on this conference call, Vaxart might make forward-looking statements, which include statements regarding the company's financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress, including statements about clinical trials that are ongoing or planned. Actual results could differ materially from those we discuss in these forward-looking statements because of a number of important factors, including uncertainty inherent in the clinical development and regulatory process, as well as other risks described in the Risk Factors section of Vaxart's most recently filed annual report on Form 10-K and in other periodic reports filed with the SEC. Vaxart undertakes no obligation to update any forward-looking statements after the date of this call. I'll now hand the call over to Steven Lo. Steve?
Steve Lo
executiveThank you, Ed, and I appreciate everyone being with us this afternoon. Today's call will open with a business overview from me; after that, James and Sean will take over to walk through the newest progress on our clinical and preclinical programs. Jeroen will then provide an update on our financials. And last, before we begin taking your questions, I'll offer a few remarks regarding our stock listing. Let me start with the COVID-19 clinical program. Last week, a second stop work order notice arrived for our Phase IIb trial, issued by Advanced Technology International, or ATI, which serves as the consortium management firm for the Rapid Response Partnership Vehicles and is funded by BARDA. Just like the initial stop work order, this one arrived unexpectedly, with no prior warning given to us. That differs from the first stop work order notice, at which point nobody had yet been enrolled in the 10,000-participant cohort. We felt fortunate that this one reached us after roughly 5,000 participants had already been enrolled. The notice also permits us to keep the study going for those who are already enrolled. Our belief remains firm that enormous potential exists for our promising oral pill vaccine candidate for COVID. Since the first participant was dosed in late May, enrollment in this trial had been moving ahead swiftly. Such trends underscore the substantial public interest in our oral vaccine platform and in a safe and effective vaccine against the SARS-CoV-2 virus. We share Secretary Kennedy's priorities, which include developing safe and effective novel vaccine solutions like our oral vaccine platform. As a reminder, the design of our trial is meant to evaluate the safety, immunogenicity and efficacy profiles of our candidate against an mRNA comparator. This trial has been built specifically to generate head-to-head data, with the aim of advancing broader and innovative vaccine technologies. Even though our trajectory had us on pace to complete enrollment of this trial by mid-Q4, as projected, or perhaps sooner, we stay encouraged regarding the prospects of the trial and our vaccine candidate, given that data will be available on about 5,000 participants. We continue communicating closely with our BARDA partners and ATI, who have said a follow-up notice containing additional details is forthcoming. I want to voice my gratitude for the efforts of our clinical teams and investigators at our sites as they carried on the important follow-up work for this trial. Our thanks also go to the clinical trial participants, whose strong interest is what makes this key study possible. COVID is still an endemic infection whose morbidity and mortality profile is worse than that of flu. And though vaccination has declined, the market opportunity is still quite significant; and naturally, we expect that our differentiated mechanism of action, combined with oral pill delivery, can alter the trajectory of vaccine acceptance and convenience. Now to our norovirus program. In June, we were happy to announce positive Phase I top-line results for our second-generation constructs, which raised norovirus blocking antibodies in both the low and high-dose cohort, with the difference hitting statistical significance in the high-dose cohort. When you look at our first-generation constructs versus the new ones, the newer version was designed to produce a more robust immune response. The full study results are going to be submitted to a peer-reviewed journal; even so, it's a positive sign that our second-generation constructs demonstrated a meaningful gain on a key marker of protection against norovirus infection. On top of that, the data keep indicating that they're well tolerated and have a favorable safety profile; in our view, this could be first-in-class or best-in-class, since right now no vaccines have been approved. Plus, other products currently in development lack the distinctive profile and the delivery benefits that our platform offers. Norovirus is in the news with ongoing outbreaks and places a heavy burden on society, so it reflects a major unmet need. As we've mentioned previously, it's thought that norovirus accounts for 20% of diarrheal disease around the world and ranks as the top cause of acute gastroenteritis, or AGE, globally; that points to the public health promise of the oral norovirus vaccine we're developing. The healthcare economic toll from norovirus infection and the AGE linked to it is put at $60 billion globally and $10 billion within the United States. That's why market research puts the potential at a multibillion-dollar U.S. market for a norovirus vaccine that's both safe and effective. After the norovirus top line data came out, members of our leadership team went to the BIO International Convention in Boston; across the conference we had a large number of productive one-on-one partnering conversations. It's still too soon to reveal particular details regarding a possible partnership, but I'm happy to report that we're seeing meaningful interest from a lot of parties. Naturally, should a partnership come together, we'll provide further information. Last, we're making headway on our preclinical work in avian influenza. Sean will point out that in a rigorous ferret clade 2.3.4.4b challenge model, our new avian influenza vaccine gave 100% protection against death, while placebo-treated animals showed 0% survival. Given the data we continue to accumulate, we see potential in our seasonal and avian influenza vaccine candidates and intend to seek funding so development of these programs can continue. All in all, our wide pipeline, with programs covering norovirus, COVID-19 and influenza, has several value-creating milestones coming up. Because our platform is built to create both systemic and mucosal immunity, we think the oral pill vaccine we have could transform global public health and bring about a revolution in how distribution and administration are done. At this point I'll hand the call to James so he can review our COVID-19 and norovirus clinical programs. James?
James Cummings
executiveThanks, Steve, and I appreciate all of you being on the call today. I'd like to begin by giving you an update on where things stand with our COVID program. Once the initial stop work order came off in April, we moved quickly to get our clinical sites up and running, restart screening of participants, and begin dosing people in the cohort of 10,000 participants — and we managed all of that in roughly 1 month. As Steve noted, we were making solid progress toward our enrollment goals, with roughly half of the participants signed up earlier this month. That said, once the newest stop work order arrived, we halted enrollment right away. One thing worth noting: the Independent Data Safety Monitoring Board, or DSMB, for this trial, whose job is evaluating how safe the trial is, concluded when it met in mid-July that the study was able to keep going with no changes needed, which gives us additional evidence regarding the safety profile of our vaccine candidate. Just to remind everyone, this Phase IIb trial is a double-blind, multicenter, randomized comparator-controlled study; the design is meant to assess relative efficacy, safety and immunogenicity of our oral COVID-19 vaccine candidate against an approved mRNA COVID-19 vaccine in adults who received prior vaccination against COVID-19. According to the stop work order notification, we'll keep carrying out a 12-month follow-up for every participant who has already received a dose in the trial, and BARDA will cover the cost. While we work out what comes next for the trial, with approximately 5,000 participants enrolled, we think we will still generate a very comprehensive data readout, which is expected in 2026. We're also carrying on with per protocol follow-up work for the 400-person sentinel cohort, which BARDA will keep funding. For the sentinel cohort, participants undergo monitoring for as long as 12 months post vaccination so that safety, immunogenicity and efficacy can be assessed. We anticipate reporting data in the first quarter of 2026. In the second quarter, we reported positive top line results from the Phase I trial that compared our first and second-generation norovirus vaccine constructs; these data demonstrated that our second-generation constructs generated higher levels of norovirus blocking antibodies than the first-generation constructs at both the high and low doses evaluated in the trial. In the high-dose cohort, that difference was statistically significant. As we've shared before, in a Phase II challenge study of the first-generation constructs, these norovirus blocking antibodies correlated with protection against norovirus infection, which showed a 30% relative reduction in the risk of infection. Our belief is that the blocking antibodies raised by the second-generation constructs will be protective against infection as well. Since the Phase I head-to-head trial demonstrated higher levels of norovirus blocking antibody with the second-generation constructs, we are optimistic this will translate into a greater reduction in infection in a field study. Our second-generation constructs, when you pair their promise with the large unmet public health need and the commercial opportunity that exists for a norovirus vaccine that is both safe and effective, give us a real chance to bring in more funding and keep this program moving. Should a partnership come together or should other money become available, the program has a path to a Phase IIb study during the second half of 2025, and that would let us hold an end of Phase II meeting with the FDA, which could pave the way for kicking off Phase III trials as soon as 2026. At this point I want to turn things over to Dr. Sean Tucker, who will walk us through the newest updates from the avian flu preclinical program. Sean?
Sean Tucker
executiveThank you, James. As a lot of you already know, the H5N1 strain of bird flu is spreading among wild birds across the world, and it's triggering outbreaks in poultry and dairy cattle within the United States. The U.S. Centers for Disease Control and Prevention reports that 70 human cases of H5N1 infection have been documented since this outbreak started, and that has led to 1 death. This virus isn't confined to the U.S. — cases have also been reported in Southeast Asia and elsewhere. The World Health Organization says Cambodia saw 15 laboratory confirmed human infections with avian flu during this year. Right now there's no known evidence that it passes person-to-person, but as the virus keeps circulating, the chance grows that mutations could arise, making animal to human transmission simpler or even leading to human-to-human spread. On top of that, people who currently work with Gary Herds at poultry farms, or who come into contact with animals that might be infected, could stand to gain from a safe and effective avian flu vaccine. One major advantage of our extensive vaccine platform development is that it lets us formulate and evaluate novel vaccine constructs rapidly. Because the avian flu threat may be growing, we managed to create a new avian flu construct and begin preclinical evaluation of it in only a few months. After that, we ran a challenge study on this construct, and it showed 100% survival along with a reduced viral load. For this study, ferrets got two vaccinations — either an old H5 vaccine, a new H5 vaccine, or placebo. Eight weeks after the first vaccination, they were challenged intranasally with H5N1. Among the ferrets that received the new H5 vaccine, 100% survived, whereas every animal given placebo had died by day 6 post challenge. Three of 8 animals that got the old vaccine were still alive 9 days after challenge; beyond the survival benefit seen with the new vaccine, the study revealed a greater than 2 log reduction in nasal wash viral load among ferrets that received a new vaccine. And this decrease was statistically significant when compared with the old vaccine and placebo; we think these data are highly compelling and could support a partnership or business development opportunity; we plan to report the data from these and other studies of our avian flu vaccine candidate in a peer-reviewed journal or peer-reviewed medical or scientific conference. I'll now hand the call over to Jeroen for a brief discussion of our financials. Jeroen?
Jeroen Grasman
executiveThanks, Sean. Today's press release lays out the specifics of how we performed financially in the second quarter of 2025. We brought in $39.7 million in revenue during the second quarter of 2025, up against $6.4 million in the second quarter of 2024. Most of that second quarter 2025 revenue came from the BARDA contract we were awarded in June 2024. The revenue we recorded in the second quarter of 2024 largely stemmed from a different BARDA contract, one granted in January 2024. As the second quarter closed, Vaxart held $26.3 million in cash, cash equivalents and investments. Under the plan we have right now, Vaxart anticipates its cash will last into the first quarter of 2026. To push that runway out further, Vaxart will keep being aggressive about looking for strategic partnerships and going after other nondilutive funding options; on top of that, after cutting roughly 10% of our workforce in the first quarter of 2025, the company carried out one more workforce reduction in the second quarter, shrinking headcount by about another 21% so that operating costs come down and our workforce lines up better with what the business requires. At this point I'll hand the call back to Steve for his closing remarks.
Steve Lo
executiveThanks, Jeroen. Before we get to your questions, I want to spend a few moments updating everyone on where things stand with our stock listing. Many of you listening already know that trading of our shares on NASDAQ has been halted, and the reason is that we no longer satisfy the exchange's requirement of a $1 minimum bid price. Starting on July 8, our common stock has been quoted on the OTCQX best market. That venue does sit at the top tier within the OTC Markets Group, but our objective remains getting back into compliance with NASDAQ so trading can pick up again there. We're still weighing every avenue available to us as we work toward having NASDAQ remove the suspension of our common shares, and we're grateful for the ongoing backing we receive from our stockholders. Our view continues to be that a NASDAQ listing represents the strongest path forward for Vaxart. Tomorrow we're scheduled to meet with the NASDAQ Hearings Panel, where we'll lay out our strategy for returning to compliance — which, given where our share price sits right now, means carrying out a reverse stock split. Once we hear a decision, we'll pass along an update. That said, we can't guarantee NASDAQ will go along with what we've proposed. With that in mind, we've called a special meeting of stockholders, set for September 5 at 8:30 a.m. Pacific Time and to be held virtually, and we're urging everyone to vote in favor of the reverse stock split proposal. When we held our annual meeting back in June, a comparable proposal failed, since a large number of our stockholders then felt that if Vaxart were trading on the OTC, our share price would climb on its own and give us an easier route to a NASDAQ listing. As we've said before, we don't think the current price of our stock comes anywhere near what we see as the true worth of this company. Even so, ever since we moved to the OTC, our share price hasn't risen in any significant way, and it has traded in a range from $0.26 to $0.47. Institutional investors and passively managed index funds tend to find us less appealing, since they frequently operate under mandates that prohibit putting money into companies listed on the OTC. On top of that, after BARDA issued its stop work order notification, getting relisted on NASDAQ matters more than it ever has. Firms listed on NASDAQ are generally regarded more positively when it comes to possible partnerships, which makes this an essential move for any collaborations down the road. Given all of this, we hold a strong conviction that a yes vote on the proposal serves the best interests of Vaxart and of all of you, our stockholders. To get ahead of questions about this proposal, along with other questions stockholders commonly raise, we'll be hosting a live fireside chat on August 20, 2025, beginning at 4:30 p.m. Eastern Time. We'd love for you to send your questions beforehand to ir@vaxart.com, or submit them live via the webcast player. We'll answer as many as we can, with the goal of earning your vote. One more reminder: should we obtain stockholder approval before we move ahead with effecting a reverse split, our first step will be to assess our circumstances and gauge how likely we are to regain compliance with NASDAQ. Even as we pursue getting back into good standing with NASDAQ, the people handling our trials, our interactions with regulators, and our day-to-day operations are performing at a very strong level, which is what let us announce encouraging results and reach important targets on the schedules we had set out. The data from our Phase I norovirus study, the headway made on our COVID-19 Phase IIb trial, and the strong preclinical findings all provided further confirmation and drew additional attention to our pioneering oral pill vaccine candidates; we are eager to update you on what comes next. I appreciate everyone spending part of your day with us. At this point, we are ready to answer your questions. Because a fireside chat is already on the calendar, we ask that anything touching on our proxy be held for that fireside chat. Operator, please go ahead and open the line.
Liang Cheng
analystThis is Liang Cheng, filling in for Roger. Congratulations on how quickly the COVID trial has been enrolling. So here's what I'd like to ask about that COVID trial. At this point you've got 5,000 people enrolled, plus the 400 in the sentinel cohort who are still being followed. Let's suppose you keep following the patients already enrolled the way the protocol lays out. What statistical assumptions and plan would you have for that, when it comes to comparing immunogenicity and efficacy against the comparator arm? And could you also just briefly verify that the current enrollment of roughly 5,000 is split about 1:1 across the 2 arms?
Steve Lo
executiveLiang, I appreciate the question; Steve here. Yes. So before I hand things to James, let me say we're extremely happy with how fast enrollment has gone since this trial began in April. Reaching 5,000 was definitely no minor achievement. And of course, credit goes to the participants and to our clinical study sites. As for your questions about the statistics and the ratio, I'll pass those to James.
James Cummings
executiveAppreciate that, Steve, and thank you as well, Liang. So the study has enrolled roughly 5,000 people, or about 5,000, up to this point. And from a scientific as well as a regulatory perspective, that's probably going to give us some highly valuable data. As for the statistical analysis plan, we are taking another look at it at this moment so that these data get used as well as they possibly can be. And just to confirm, the listing for this was a randomized study; therefore approximately half of the participants are going to get our test construct, while the remaining half are going to get a comparator mRNA.
Liang Cheng
analystUnderstood. Then perhaps one more thing on that topic. So putting it differently, if your enrollment were to pick back up in the direction of the 10,000 target. Then what do you anticipate regarding how that pace of enrollment would affect the second stop order?
James Cummings
executiveThat, Liang, I suppose, hinges on timing. It hinges on the point at which any modifications could take place. Regarding where we'd stand on enrollment, here's what I can tell you. So more details are what we're awaiting. Once we have that clarity, we will definitely provide an update.
Cheng Li
analystPerhaps I'll start with the norovirus program — and once more, congratulations on the quite striking results you reported in June. I'm curious, though: I believe you said that moving ahead to the Phase IIb trial depends on a partnership or extra funding. So I'd like to verify that you must obtain financing or a partner before launching that Phase IIb study. And a connected thing, maybe: what's the soonest realistic point at which the Phase IIb study could begin? Then I have one more question after that.
Steve Lo
executiveCheng, I appreciate the question. Sure — as far as what you're asking, I'll hand it to Jeroen. Still, from where we sit, let me just note that following our June data release, we've held a number of productive discussions with prospective partners, and Jeroen is able to address the funding piece specifically.
Jeroen Grasman
executiveYeah. Regarding the money side, we've said before too that how this trial moves forward depends on getting funded — whether that comes through a partner or through outside sources of funding, it's going to hinge on that.
Cheng Li
analystUnderstood. Beyond the money, is there anything else that could act as a gating item?
Steve Lo
executiveYeah, Cheng, nothing like that has come to our attention. What it comes down to, honestly, is the financing. You're clearly familiar with the data, and producing it was something we were glad to do; we've actually already begun preparing for the next steps, including things like CROs and so on. So the gate here is essentially the funding, more than anything else.
Cheng Li
analystOkay. Then perhaps a question regarding the COVID-19 program. Could you possibly provide some specifics about why that second stop work order was issued, and do you believe there is any way enrollment might start up again for this program?
Steve Lo
executiveCertainly. As we mentioned during our opening remarks, no particular explanation has come to us about the reasoning. Our response was, naturally, to comply with the work order. Consequently, we stopped adding any further participants to the trial. We feel quite pleased to be at approximately 5,000. Honestly, I believe we are simply awaiting additional details from BARDA. Conversations with them have taken place, yet the specific rationale has not arrived so far.
Mayank Mamtani
analystSo, you've had a bit of time now to process the norovirus Phase I data and perhaps, as you noted, receive some strategic feedback at BIO. Is there a specific deal structure or economic model that strikes you as the most attractive and realistically achievable? And have you gotten any feedback regarding the development plan, including the potential correlates of protection you're going after? Then I have one quick follow-up.
Steve Lo
executiveGreat. Mayank, I appreciate the question. James or Sean will handle the second one. As for the first, we've made it quite clear that we remain agnostic. From both the science side and the clinical development side, I believe it matters that we intend to advance into Phase II. So we aren't imposing any rigid conditions that it must be set up in a particular manner, and so on. We're definitely open to co-development and licensing — what matters is keeping the science progressing; we've maintained a very open-minded stance on that. And Mayank, I apologize, could you repeat the second question, just for Sean and James?
Mayank Mamtani
analystYes. Any thoughts on the development plan you're considering, and also the potential correlates of protection you're thinking about, drawing on what regulators have told you before? Anything you can share on that?
Steve Lo
executiveYes. Sean, go ahead.
Sean Tucker
executiveRight. The main point, I'd say, is that the challenge study clearly tells us which correlates matter most. Those are what we need to track so we can demonstrate that immunogenicity looks strong and would predict success. Still, what really matters with that Phase II trial is gathering sufficient numbers on the safety side so we can move ahead to an end of Phase II meeting with the FDA.
Mayank Mamtani
analystAll right. And regarding the avian flu data as well — are there plans for a publication? And what would the process look like for obtaining, perhaps, a federal funding mechanism there? And finally, Jeroen, when it comes to R&D spend going forward, how should we be thinking about that? And should we assume the spend profile that you have will basically be reimbursed in some manner and won't be affected by the stop work order?
Sean Tucker
executiveYes. Mayank, I believe the critical piece when it comes to the publication is getting the paper written. And clearly, the data has only recently come out. So there's a bit of work for us to do. As for the kind of funding, I mean, again, this is avian flu. There's substantial need. There's a great deal of circulating virus in cattle and poultry. And we believe there's a solid opportunity to, in a sense, target people who may be exposed to this. So that would be our next bet.
Jeroen Grasman
executiveNow regarding the R&D costs, when you look at each stop work order, our read is that BARDA is going to keep paying for the per-protocol follow-up, both safety and efficacy, covering the roughly 5,000 participants who have received doses so far. And because there are significant fixed-cost pieces involved in conducting a clinical trial, we do expect that more than 50% of the original contract will be collected.
Ed Berg
executiveThanks, operator, and I appreciate all of you sending in your questions. A few of them concern the COVID-19 program. The first one is directed at James. If a Phase IIb clinical trial with 5,000 participants goes forward — basically on the assumption that the stop work order remains in effect — would that yield data that's useful for supporting the product's development plan?
James Cummings
executiveAppreciate that, Ed. So, a Phase IIb trial involving roughly 5,000 people — it stands a strong chance of yielding quite valuable information on the scientific side as well as for regulatory purposes. Once more, we're taking another look at the statistical analysis plan, purely to make sure we're getting the greatest possible value out of these data in backing the product's development.
Ed Berg
executiveOne more question about COVID. Could the stop work order actually end up benefiting you and speed up your schedule? James, any sense of what the time line looks like?
James Cummings
executiveSure; so in the event that the stop work order prevents us from enrolling any further patients or subjects. Our top line data reporting timeline is actually somewhat ahead of what we had anticipated. Just to remind everyone, this trial called for a 12-month follow-up period after vaccination for the final individual dosed, in order to evaluate safety, immunogenicity and efficacy.
Edward Berg
analystAll right. And James, the last thing for you relates to COVID. Even though uptake of the authorized mRNA vaccines has been lower, what makes you believe the trial managed to enroll people at such a quick rate?
James Cummings
executiveOkay, so the demand to take part in our COVID clinical study was definitely strong. I'd like to recognize and express gratitude to every participant, all the study sites, and honestly everyone who helped us get roughly 5,000 participants enrolled so quickly. In my view, that fast enrollment rate really demonstrates how much people want an improved COVID vaccine. Even as the SARS-CoV-2 virus keeps mutating and stays widespread across the globe, we're eager to examine the data, and it could be ready for the study participants who have already received their doses as soon as late 2026.
Ed Berg
executiveAlright, moving on to some norovirus questions. James, I'll go to you once more. When it came to the top line Phase I data for norovirus that came out in June, did anything catch you off guard?
James Cummings
executiveThose were statistically significant, correct? Even though the trial lacked the statistical power to establish superiority, the rise in MBAA titers from the second-generation constructs was big enough — 141% with the G11 construct and 94% with the G24 construct. That shows statistical significance at the higher dose, and that's the reason we pivoted to the new construct high dose.
Ed Berg
executiveRegarding noro, James, let me pause you briefly and turn to Steve. For noro, how near is the company to securing a partnership? And I realize you discussed structure, but what's the status on timing?
Steve Lo
executiveAbsolutely. I appreciate you asking. Like I mentioned before, during June at BIO we held a number of quite productive one-on-one meetings, and from that point forward, talks with those prospective partners have kept going. Since these conversations are confidential in nature, providing any guidance on timing is difficult for us. That said, whenever we reach the stage where something can be announced, we will make it public. What I do want to convey is that dialogue with these parties is still ongoing, and it appears to be genuinely fruitful. Quite often, what they're looking for is the opportunity to review certain trial data and similar materials.
Edward Berg
analystSean, I'd like to ask you something. That breast milk study produced encouraging findings. Has there been any talk of conducting an additional trial, so we can learn more about whether passive immune transfer is possible?
Sean Tucker
executiveYeah. Clearly, the study gave us some strong results, and we're still working out what to do next. The moment we reach a decision, we'll announce it; that said, a lot hinges on funding, which really highlights how critical it is for us to tap into money from many different places. The upcoming study will probably be paid for through nondilutive funding or by teaming up with a partner.
Edward Berg
analystOkay, thanks. Sean, here's another one for you — there's been talk in the news about whole inactivated virus vaccines. So how do Vaxart's construct and Vaxart's results stack up against those whole inactivated virus vaccines?
Sean Tucker
executiveOkay, so in clinical trials, whole inactivated viruses targeting SARS-CoV-2 haven't performed all that well when you put them up against mRNA. We haven't run a head-to-head comparison with those. That said, if our results in the BARDA-backed study match or exceed what mRNA achieved, then we'd anticipate outperforming whole inactivated viruses too.
Ed Berg
executiveThere's one additional item, and it might be for Steve or for Jeroen. Since the cash we have takes us into 2026, which approaches to raising capital are you currently looking into?
Jeroen Grasman
executiveAbsolutely, we've been having active conversations—as Steve pointed out—with a number of potential partners about our vaccine platform and programs, and that definitely covers COVID, norovirus, and flu. Those potential partners span both regional and global pharma companies. That said, I'd also like to stress that we stay very disciplined when it comes to controlling our costs and making sure resources are allocated in the best possible way, so that we can stretch out our cash flows.
Steve Lo
executiveAbsolutely. I also want to say how much we value the dedication our employees have shown. As Jeroen noted at the start, we did have to cut certain workforce-related costs. That is never easy for us. Like Jeroen said, we explore many different ways to bring in capital while also keeping our spending in check. I will say this, and we will keep pushing on this point: we believe a NASDAQ listing would clearly make us stronger in both partnership talks and upcoming financings. Once again, we urge our shareholders to support the reverse stock split. We will gladly take questions now. The entire management team will be present at the fireside chat next week.
Ed Berg
executiveAll right. That wraps up the Q&A portion. I'll hand things back to the operator now. Thanks — let's go ahead and close this out.
Operator
operatorThanks very much, sir; that brings today's conference to a close. At this point you're free to disconnect your lines. We appreciate your participation.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.